Core Viewpoint - The approval of the IND for CS2009, a tri-specific antibody therapy, marks a significant advancement for the company in the treatment of advanced solid tumors, indicating strong confidence in its clinical development potential [1] Company Summary - The company announced that its CS2009 therapy, which targets PD-1, VEGF, and CTLA-4, has received approval for a Phase II clinical trial in China [1] - The CEO, Dr. Yang Jianxin, expressed confidence in accelerating the Phase II study based on promising preliminary data from the Phase I trial [1] - The Phase II trial will utilize a multi-cohort parallel expansion design, covering 15 monotherapy and combination therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The trial is currently enrolling participants in Australia, and the approval in China is expected to expedite the clinical development process [1]
基石药业-B宣布CS2009(PD-1/VEGF/CTLA-4三特异性抗体)Ⅱ期临床试验联合疗法IND在中国获批，深入探索三抗治疗潜力